• AngII Drives M1 Macrophage Polarization via Cx43/NF-κB Pathw

  2026-05-26

  This study demonstrates that angiotensin II (AngII) promotes M1-type polarization of RAW264.7 macrophages through activation of the connexin 43 (Cx43)/NF-κB signaling pathway. The findings clarify a mechanistic link between Cx43 hemichannels and pro-inflammatory macrophage responses, with implications for cardiovascular disease and inflammation research.

• ALDH2 Inhibition Triggers Synthetic Lethality in APC-Deficie

  2026-05-26

  A recent study demonstrates that inhibiting ALDH2 with Disulfiram selectively induces apoptosis and suppresses tumor growth in APC-deficient colorectal cancer, acting via ROS/ASK1/JNK pathway activation. These findings highlight synthetic lethality as a promising strategy for targeting hard-to-treat colorectal tumors with frequent APC mutations.

• Translational Ligand Discovery: Mechanistic Rigor Meets Stra

  2026-05-25

  Explore how advanced compound libraries, exemplified by the DiscoveryProbe™ Bioactive Compound Library Plus, are reshaping translational research. This article fuses mechanistic insights with actionable guidance for leveraging high-throughput ligand screening, with a special focus on bacterial sensor proteins, cancer biology, and immunology. Integrating the latest evidence on thermal shift assays and pathway analysis, we chart a path for researchers seeking both scientific depth and operational efficiency.

• Firefly Luciferase mRNA: Enhancing mRNA Delivery & Assays

  2026-05-25

  EZ Cap™ Firefly Luciferase mRNA (5-moUTP) streamlines bioluminescent reporter workflows with superior translation efficiency and immune evasion. This advanced 5-moUTP modified mRNA supports robust delivery, reproducible signal, and minimal background, making it the trusted choice for cutting-edge mRNA functional assays.

• HBsAg Diverts TBK1 to Suppress Interferon and Trigger Autoph

  2026-05-24

  This study uncovers how hepatitis B surface antigen (HBsAg) manipulates TANK-binding kinase 1 (TBK1) to suppress type I interferon signaling and induce early autophagy, facilitating persistent HBV infection. The mechanistic insight into TBK1 dimerization and disrupted IRF3 activation highlights new intersections between innate immunity and autophagy, with implications for antiviral and autophagy-targeted research.

• Gap26 Connexin 43 Mimetic Peptide: Mechanism, Evidence, and

  2026-05-23

  Gap26 is a selective connexin 43 mimetic peptide that blocks gap junction communication and inhibits ATP and calcium signaling in 3D cell networks. Peer-reviewed studies validate its role in dissecting intercellular communication and calcium wave propagation in vascular and neural models.

• KU-55933 in iPSC-Based Precision Disease Modeling: New Horiz

  2026-05-22

  Explore how KU-55933, a potent ATM kinase inhibitor, is advancing DNA damage response research through iPSC-based precision disease modeling. Discover unique assay strategies and clinical insights not covered in standard reviews.

• Applied ddhCTP: Antiviral Workflows & Troubleshooting Insigh

  2026-05-22

  Harnessing ddhCTP (3ʹ-deoxy-3′,4ʹ-didehydro-CTP) transforms bench virology by enabling targeted RNA virus inhibition in both cellular and in vitro systems. This guide distills protocol enhancements, advanced applications, and troubleshooting tactics that streamline the path from mechanistic insight to robust antiviral assay deployment.

• ATM Inhibition, Genome Security, and Translational Leverage

  2026-05-21

  Explore the mechanistic, experimental, and strategic dimensions of ATM kinase inhibition with KU-55933 in contemporary DNA damage response research. This article connects recent advances in nuclear cGAS biology, L1 retrotransposition, and the practical deployment of ATM inhibitors, offering actionable guidance for translational scientists seeking to drive innovation in cancer, aging, and genome stability studies.

• BCL6 Drives Immune Evasion in Hepatocellular Carcinoma via C

  2026-05-21

  This study uncovers how B cell lymphoma 6 (BCL6) facilitates immune escape in hepatocellular carcinoma (HCC) by suppressing the cytotoxic function and recruitment of tumor-infiltrating CD4+ T cells through ESM1 regulation. The findings provide significant insight into the mechanisms limiting immunotherapy efficacy in HCC and highlight new strategies for targeting tumor immune evasion.

• DMH-1: Redefining Organoid and NSCLC Research with Selective

  2026-05-20

  This thought-leadership article explores how DMH-1, a highly selective ALK2 inhibitor, is advancing the field of translational research by enabling precise modulation of BMP signaling in both organoid systems and non-small cell lung cancer (NSCLC) models. Integrating mechanistic insights with strategic recommendations, we examine recent breakthroughs in tunable organoid technology, experimental validation in cancer research, and the broader impact on high-throughput screening and personalized medicine.

• Streptavidin – Cy5: Optimizing Biotin Detection in Oncology

  2026-05-20

  Streptavidin – Cy5 pairs high-affinity biotin binding with Cy5 fluorescence, delivering ultrasensitive, quantitative detection in immunofluorescence and flow cytometry. This guide translates recent bench research into best practices for oncology workflows, troubleshooting, and protocol optimization using APExBIO's trusted reagent.

• Uridine, Trisodium Salt: Empowering Precision RNA Transgenes

  2026-05-19

  This thought-leadership article explores the evolving landscape of RNA-driven genome engineering, spotlighting Uridine, Trisodium Salt as a pivotal nucleoside analog for translational researchers. By connecting mechanistic insights from non-LTR retroelement-mediated transgene insertion to practical workflow enhancements, we reveal how this high-purity reagent from APExBIO advances precision, reliability, and reproducibility in RNA biosynthesis and gene insertion studies. The narrative synthesizes recent advances, protocol guidance, and strategic outlook for maximizing impact in translational pipelines.

• Testosterone Bounce as a Prognostic Biomarker in Prostate Ca

  2026-05-19

  The referenced study demonstrates that a 'testosterone bounce'—a temporary rise in serum testosterone above 20 ng/dL after nadir—predicts improved overall and cancer-specific survival in prostate cancer patients treated with the GnRH antagonist degarelix. This finding advances biomarker-driven prognosis beyond PSA levels and may influence future stratification of hormone therapy response.

• Nicotinamide Adenine Dinucleotide (NAD+): Applied Workflows

  2026-05-18

  Unlock the power of Nicotinamide Adenine Dinucleotide (NAD+) as a research-grade coenzyme for dissecting metabolic signaling and cellular stress adaptation. This article delivers advanced workflows, actionable troubleshooting tips, and novel insights from recent breast cancer studies—equipping your lab for reproducible, publication-quality results.

583 records 10/39 page Previous Next First page 上5页 678910 下5页 Last page